+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent FDA-approved Therapeutics

  • ID: 4206060
  • Report
  • 15 pages
  • Frost & Sullivan
1 of 2
This Genetic Technology TOE profiles therapeutics that have been recently approved by FDA. The corresponding clinical trials scenario is also depicted along with industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 2
Innovation Profiles:
  • First FDA Approved Immunotherapy for Metastatic Merkel Cell Carcinoma
  • Relapsing Multiple Sclerosis Now Has a Novel FDA-approved Drug for Treatment
  • FDA-approved Therapy for Atopic Dermatitis
  • Suitable and Effective Therapeutic Approved for Recurrent Epithelial Ovarian Cancer
  • Ovarian Cancer Clinical Trials
  • Industry Contacts
Note: Product cover images may vary from those shown
3 of 2